Articles

Results 1 to 5 of 5


Obviousness: Cannot Forget the Motivation to Combine or Modify

USA - September 2 2022 In Tris Pharma Inc. v. Actavis Laboratories FL, Inc., No. 21-1495 (Fed. Cir. July 7, 2022) (non-precedential), the Court of Appeals for the Federal…

Adriana L. Burgy, Thomas L. Irving, Stacy Lewis, Melanie Magdun

When “Good Enough” Is Good Enough for Finding Obviousness

USA - August 2 2022 In Cornell Research Foundation, Inc. v. Vidal, No. 2020-2334, 2022 WL 1634223 (Fed. Cir. May 24, 2022) (non-precedential), the Court of Appeals for…

Thomas L. Irving, Stacy Lewis, Amanda K. Murphy, Emma N. Ng, Shannon M. Patrick

“Show More of You”: Amgen v. Sandoz, Battling it Out on Amgen’s Otezla® Drug

USA - January 18 2022 In the Hatch-Waxman patent infringement case Amgen, Inc. v. Sandoz Inc., Civ. Action No. 3:18-cv-11026, Judge Shipp of the District Court of New…

Thomas L. Irving, Stacy Lewis, Jill K. MacAlpine, Ph.D., Paul W. Browning Ph.D., Melissa C. Santos, Ph.D.

Patent Owner Loses Everything at PTAB

USA - December 1 2021 In Mati Therapeutics, Inc. v. Ocular Therapeutix, Inc., the Federal Circuit issued a Rule 36 opinion affirming the Patent Trial and Appeal Board’s…

Thomas L. Irving, Stacy Lewis, Emma N. Ng, Paul W. Browning Ph.D.

A Mixed Bag: Some Claims Found Unpatentable but Others Are Patentable

USA - November 15 2021 In Liquidia Technologies, Inc. v. United Therapeutics Corp., IPR2020-00770, Paper 45 (P.T.A.B. Oct. 8, 2021), the Patent Trial and Appeal Board…

Thomas L. Irving, Stacy Lewis, Amanda K. Murphy, Jill K. MacAlpine, Ph.D., Melissa C. Santos, Ph.D.